Research peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
A meta-analysis of bright light therapy commissioned by the American Psychiatric Association found a significant reduction in depression symptom severity associated with bright light treatment. Benefit was found for both seasonal affective disorder and for nonseasonal depression, with effect sizes similar to those for conventional antidepressants. For non-seasonal depression, adding light therapy to the standard antidepressant treatment was not effective. A meta-analysis of light therapy for non-seasonal depression conducted by Cochrane Collaboration, studied a different set of trials, where light was used mostly in combination with antidepressants or wake therapy. A moderate statistically significant effect of light therapy was found, with response significantly better than control treatment in high-quality studies, in studies that applied morning light treatment, and with patients who respond to total or partial sleep deprivation. Both analyses noted poor quality of most studies and their small size, and urged caution in the interpretation of their results. The short 1–2 weeks duration of most trials makes it unclear whether the effect of light therapy could be sustained in the longer term.
== See also == Flags of the Soviet Republics Emblems of the Soviet Republics Commonwealth of Independent States Eurasian Economic Union National delimitation in the Soviet Union Bavarian Soviet Republic Hungarian Soviet Republic Slovak Soviet Republic Limerick Soviet Paris Commune Provisional Polish Revolutionary Committee (Polish SSR) Republics of Russia Federal subjects of Russia Post-Soviet states (former Soviet Republics)
=== Devices === Graphene's modifiable chemistry, large surface area per unit volume, atomic thickness and molecularly gateable structure make antibody-functionalized graphene sheets excellent candidates for mammalian and microbial detection and diagnosis devices. Graphene is so thin that water has near-perfect wetting transparency which is an important property particularly in developing bio-sensor applications. This means that a sensor coated in graphene has as much contact with an aqueous system as an uncoated sensor, while remaining protected mechanically from its environment.
=== EC 1.1.5 With a quinone or similar compound as acceptor === EC 1.1.5.1: deleted, see EC 1.1.99.18 cellobiose dehydrogenase (acceptor) EC 1.1.5.2: quinoprotein glucose dehydrogenase EC 1.1.5.3: glycerol-3-phosphate dehydrogenase (quinone) EC 1.1.5.4: malate dehydrogenase (quinone) EC 1.1.5.5: alcohol dehydrogenase (quinone) EC 1.1.5.6: formate dehydrogenase-N EC 1.1.5.7: cyclic alcohol dehydrogenase (quinone) EC 1.1.5.8: quinate dehydrogenase (quinone)
== Pathophysiology == TANGO2 plays role in mitochondrial β-oxidation, consequently in that disease, β-oxidation and ATP levels are reduced (especially under stress). Interestingly TANGO2 also might participate in retrograde ER-Golgi trafficking, consequently this process is slowed down in this disease, and the supplementation of TANGO2 has restored that process. According to one study, TANGO2 also might participate in autophagy process, which might be responsible for rhabdomyolysis in this disease.
Sources: en.wikipedia.org
Viola arvensis is a species of violet known by the common name field pansy. It is native to Europe, western Asia, and North Africa, and it is known on other continents as an introduced species and a weed of disturbed and cultivated areas. Viola arvensis was shown to contain cyclotides, a class of peptides found in plants. The peptide cycloviolacin O2 in particular has shown to possess cytotoxic activity against human cancer cells and is therefore looked at as a potential drug lead.
==== By phosphate ==== In cyanobacteria, inorganic phosphate (Pi) also participates in the co-ordinated regulation of photosynthesis: Pi binds to the RuBisCO active site and to another site on the large chain where it can influence transitions between activated and less active conformations of the enzyme. In this way, activation of bacterial RuBisCO might be particularly sensitive to Pi levels, which might cause it to act in a similar way to how RuBisCO activase functions in higher plants.
=== 31 January === US President Joe Biden said no to sending F-16s fighter jets to Ukraine after being asked by a reporter. A spokesman for British PM Rishi Sunak said it was not practical for the UK to supply Ukraine with fighter jets. Two US government officials said that the US was preparing a $2 billion aid package to Ukraine which included Ground Launched Small Diameter Bombs with a range of around 150 km (93 mi).
== History == Fujirebio was founded in Tokyo, Japan in 1950 under the name Fujizoki Pharmaceutical, Co., Inc. In its early days the company developed and manufactured pharmaceutical products. The company's first IVD test was launched in 1966, a TPHA kit for syphilis testing. In 1983 the company changed name to Fujirebio Inc. Between 1998 and 2010 Fujirebio acquired several specialized IVD companies, notably Centocor Diagnostics (1998), CanAg Diagnostics (2006) and Innogenetics (2010). In 2005, Fujirebio Inc. was integrated together with the commercial laboratories SRL, Inc. ("Special Reference Laboratories", established in 1970) under the holding company Miraca Holdings Inc. (which was renamed to H.U. Group Holdings, Inc. in 2020). The current company structure, Fujirebio Holdings, Inc. was created in 2017 as a parent company of Fujirebio Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe N.V. and other Fujirebio group companies. In 2022, Fujirebio acquired respectively the companies ADx NeuroSciences and Fluxus, Inc. In 2025, Fujirebio acquired Plasma Services Group, Inc.
== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed DIC is a strong skin sensitizer, showing a response at 0.20 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. Thermal hazard analysis by differential scanning calorimetry (DSC) shows DIC poses minimal explosion risks.
Sources: en.wikipedia.org
== Medical uses == Amitriptyline/chlordiazepoxide is used for the treatment of moderate to severe depression associated with moderate to severe anxiety. It has shown to be more effective in treating symptoms of anxiety, irritability, and hostility in patients with comorbid depression and anxiety than amitriptyline alone. It also has a quicker onset time than either amitriptyline or chlordiazepoxide on their own.
== Side effects == The most common side effects are flatulence (in 5% of people taking the drug), diarrhea (4%), constipation (4%), stool color change (4%), nausea (3%), vomiting (3%), and abdominal discomfort, bloating and pain (1%). Ferric maltol may cause serious side effects including increased risk of inflammatory bowel disease flare and iron overload in the body.
== Partnerships == Pilot uses the lure of celebrities in their marketing, including players from the NRL team, the Cronulla Sharks, for which Pilot is a named sponsor. Mixed martial arts star Jack Della Maddalena and Australian swimmer James Magnussen have also been featured. In 2022, Pilot donated AUD $120,000 to the free phone counselling service, This is a Conversation Starter (TIACS).
There has been a global increase in food insecurity and hunger between 2011 and 2020. In 2015, 795 million people (about one in ten people on earth) had undernutrition. It is estimated that between 691 and 783 million people in the world faced hunger in 2022. According to UNICEF, 2.4 billion people were moderately or severely food insecure in 2022, 391 million more than in 2019.
=== Mechanisms and therapeutics for neurodevelopmental disorders === Sur’s group has applied this understanding of plasticity to study disorders of brain development. Rett Syndrome is a devastating neurodevelopmental disorder caused by mutations in MECP2, a transcriptional regulator. Sur hypothesized that a core mechanism of Rett Syndrome is the persistence of immature synapses which may be induced to mature. Rett model mice indeed have a deficit in PI3K/Akt/Erk signaling and PSD95 expression, leading to immature excitatory synapses and prolonged visual cortex plasticity that extends into adulthood. Application of IGF1(1-3) peptide, which degrades IGF binding proteins produced by astrocytes and enhances IGF1 availability, and of full-length IGF1, upregulates these signals to restore normal synaptic plasticity and function and improve behavioral phenotypes. Human Rett IPSC-derived neurons show deficits in IGF1 and similar effectiveness of IGF1 in restoring PI3K, AKT and S6 signals. Based on the lab’s work, an IGF1(1-3) mimetic – trofinetide - was employed in clinical trials for Rett Syndrome. In 2023, trofinetide was approved by the FDA as the first treatment for Rett Syndrome. This work has played an important part in raising optimism that even major disorders of brain development may be treated effectively when understood mechanistically.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.